Pietro Genovese

Harvard University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index4.7kcitations69works8.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(39), CAR-T cell therapy research(37), Virus-based gene therapy research(33), RNA Interference and Gene Delivery(8), Immune Cell Function and Interaction(8)

Publications69 total

Efficient, potent, and specific near-universal base and prime editing for ELANE-mutant severe congenital neutropenia
Blood·2025
Germline SEPT6 mutations in congenital neutropenia and myelodysplastic syndrome induce de novo protein function disrupting hematopoietic stem cell maintenance
Blood·2025Open Access
Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients
Nature Communications·2024· 2 citedOpen Access
Engineered packaging cell line for the enhanced production of baboon-enveloped retroviral vectors
Molecular Therapy — Nucleic Acids·2024· 4 citedOpen Access
Epitope Editing Combined with Extended Schedule Anti-KIT Antibody Treatment Allows Immune-Based In Vivo Selection of Multiplex Genome-Engineered Cells
Blood·2024Open Access
1140 Engineered B cells show anti-tumor activity in preclinical model of HER2+ breast cancer
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
UNC Libraries·2024Open Access
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
UNC Libraries·2024Open Access
Author Correction: IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Nature Communications·2024· 1 citedOpen Access
Enhancing prime editing in hematopoietic stem and progenitor cells by modulating nucleotide metabolism
Nature Biotechnology·2024· 22 cited
Abstract NG05: Epitope editing enables targeted immunotherapy of acute myeloid leukemia
Cancer Research·2024
TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells
Frontiers in Immunology·2024· 21 citedOpen Access
Exonic knockout and knockin gene editing in hematopoietic stem and progenitor cells rescues RAG1 immunodeficiency
Science Translational Medicine·2024· 20 citedOpen Access
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Nature Communications·2024· 53 citedOpen Access
Epitope Edited Hematopoietic Stem Cells to Enable Synergistic Immunotherapy Combinations for Acute Myeloid Leukemia
Blood·2023Open Access
The Association of <i>SEPTIN6</i> Mutations with Pediatric Myelodysplasia
Blood·2023Open Access
Epitope Edited Hematopoietic Stem Cells Allow Immune-Based In Vivo Selection of Genome-Engineered Cells
Blood·2023Open Access
237 Epitope engineered hematopoietic stem cells to enable multi-specificity CAR-T cells for acute myeloid leukemia
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Nature·2023· 95 citedOpen Access
Targeted gene addition at the CX3CR1 locus of human HSPCs improves their ability to repopulate the myeloid CNS compartment and drives lineage specific and robust transgene expression in their CNS progeny
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Luigi Naldini(33), Angelo Lombardo(18), Michael C. Holmes(17), Chiara Bonini(14), Philip D. Gregory(13), Giulia Schiroli(11), Attilio Bondanza(10), Claudio Bordignon(10), Fabio Ciceri(9), Samuele Ferrari(9), Gabriele Casirati(9), Bernhard Gentner(8), Zulma Magnani(8), Barbara Camisa(8), Valentina Vavassori(8), Ivan Merelli(8), Elena Provasi(7), Luisa Albano(7), Gianpietro Dotti(6), Aurélien Jacob(6)